NDA 213983 · Viiv Hlthcare
Tivicay Pd
Dolutegravir Sodium · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Aug 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jun 12, 2020
Approved uses
3
Original approval plus efficacy supplements
Registered trials
306
91 Phase 3, 30 recruiting
FAERS reports
758
730 serious, 174 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 25, 2026.
TIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV ‑ 1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) weighing at least 2 kg [see Microbiology ( 12.4 )] . TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. TIVICAY and TIVICAY PD are an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but INSTI- naïve) weighing at least 2 kg. ( 1 ) TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. ( 1 )
Mechanism: Dolutegravir is an HIV-1 antiretroviral agent [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 25, 2026 Supplement 7 · Efficacy · priority review LetterLabel
- Jul 9, 2021 Supplement 2 · Efficacy LabelLetter
- Jun 12, 2020 Original approval · Type 3 - New Dosage Form · priority review LabelLetterReview
1 products under this application
- TIVICAY PD · DOLUTEGRAVIR SODIUM EQ 5MG BASE · TABLET, FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dolutegravir" as an intervention, any sponsor and status, largest first.
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTPivotal-lookingRecruiting
Africa Health Research InstituteAcademic, hospital or other
NCT06250504 · 2,052 participants (planned) · Start Feb 27, 2024 · Primary completion Apr 30, 2026
Drug: APRETUDE (cabotegravir) 600 mg\3 mL; DAPIRING (Dapivirine) 25mg Vaginal Ring and 2 more · For: HIV Infections
Sites: Somkele, South Africa
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02140255 · 1,120 participants (planned) · Start Jan 23, 2015 · Primary completion Jan 31, 2028
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP) and 5 more · For: HIV Infection
Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 47 sites in all
- ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral TherapyPivotal-lookingCompleted
Professor Francois VenterAcademic, hospital or other
NCT03122262 · 1,110 participants · Start Jan 16, 2017 · Primary completion Apr 30, 2022
Drug: Dolutegravir; Tenofovir Alafenamide and 2 more · For: HIV-1 Infection
Sites: Johannesburg, South Africa · 4 sites in all
- POC HIV Testing and Early DTG Use for InfantsActive, not recruiting
Harvard School of Public Health (HSPH)Academic, hospital or other
NCT05393193 · 900 participants (planned) · Start Jul 4, 2022 · Primary completion Mar 16, 2026
Drug: DTG/ABC/3TC · For: HIV
Sites: Gaborone, Botswana
- Antiretroviral Therapy for Acute and Chronic HIV InfectionPivotal-lookingRecruiting
SEARCH Research FoundationAcademic, hospital or other
NCT00796263 · 900 participants (planned) · Start May 13, 2009 · Primary completion Jun 2033
Drug: HAART · For: Acute HIV Infection; Chronic HIV Infection
Sites: Bangkok, Thailand
- Optimizing Malaria Treatment for HIV-Malaria Co-infected IndividualsPivotal-lookingStatus unknown
Makerere UniversityAcademic, hospital or other
NCT04708496 · 888 participants (planned) · Start Jan 18, 2021 · Primary completion Jan 2024
Drug: Artemether-lumefantrine · For: HIV Coinfection; Malaria
Sites: Kampala, Uganda; Tororo, Uganda
- Shortened Regimen for Drug-susceptible TB in ChildrenPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06253715 · 860 participants (planned) · Start Jan 15, 2025 · Primary completion Sep 30, 2027
Drug: Isoniazid; Rifampin and 4 more · For: Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node and 1 more
Sites: Chennai, India; Pune, India; Bandung, Indonesia · 9 sites in all
- A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)Pivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT01263015 · 844 participants · Start Feb 1, 2011 · Primary completion May 14, 2012
Drug: Dolutegravir; Atripla and 4 more · For: Infection, Human Immunodeficiency Virus I
Sites: Hobson City, Alabama; Little Rock, Arkansas; Bakersfield, California · 145 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- exposure during pregnancy399
- off label use331
- headache324
- immunodeficiency322
- hyperhidrosis321
- hypertension320
- hepatic enzyme increased319
- joint swelling319
- food allergy316
- pyrexia314
- asthma311
- hypersensitivity311
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 22 |
| 2019 | 16 |
| 2020 | 29 |
| 2021 | 60 |
| 2022 | 54 |
| 2023 | 191 |
| 2024 | 222 |
| 2025 | 98 |
| 2026 | 55 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tivicay Pd (Dolutegravir Sodium)
2024 spending
$38K
Beneficiaries
n/a
35 claims
Per beneficiary
n/a
$7.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $22,430 |
| 2022 | $24,727 |
| 2023 | $35,827 |
| 2024 | $37,772 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Equivalence Trial
- Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV.
Cindi Z, Kawuma AN, Maartens G, et al. · Pharmacogenet Genomics 2023 · Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.
- Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A, White E, Mujuru HA, et al. · N Engl J Med 2021 · Comparative Study, Equivalence Trial
- Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.
Figueroa MI, Brites C, Cecchini D, et al. · Clin Infect Dis 2026 · Randomized Controlled Trial, Multicenter Study
- Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency Virus.
Letendre SL, Chen H, McKhann A, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Musiime V, Bwakura-Dangarembizi M, Szubert AJ, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.